Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 4 studies | 19% ± 5% |
Insufficient scRNA-seq data for expression of NECAB3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 7137.56 | 258 / 258 | 100% | 52.48 | 230 / 230 |
ovary | 100% | 7500.89 | 180 / 180 | 100% | 46.36 | 430 / 430 |
prostate | 100% | 3935.67 | 245 / 245 | 100% | 87.29 | 501 / 502 |
thymus | 100% | 3429.26 | 653 / 653 | 98% | 22.48 | 594 / 605 |
liver | 100% | 1151.56 | 226 / 226 | 98% | 28.39 | 398 / 406 |
bladder | 100% | 2296.33 | 21 / 21 | 97% | 23.92 | 488 / 504 |
breast | 100% | 1831.00 | 459 / 459 | 97% | 38.97 | 1081 / 1118 |
intestine | 100% | 2081.36 | 966 / 966 | 97% | 22.11 | 509 / 527 |
stomach | 100% | 3004.23 | 359 / 359 | 97% | 22.20 | 276 / 286 |
brain | 97% | 1870.72 | 2565 / 2642 | 99% | 21.88 | 700 / 705 |
lung | 99% | 1953.31 | 572 / 578 | 97% | 26.85 | 1122 / 1155 |
skin | 98% | 998.33 | 1773 / 1809 | 96% | 24.22 | 455 / 472 |
uterus | 100% | 1667.59 | 170 / 170 | 94% | 21.55 | 433 / 459 |
pancreas | 100% | 1338.85 | 328 / 328 | 92% | 13.12 | 164 / 178 |
esophagus | 100% | 1989.40 | 1443 / 1445 | 91% | 15.56 | 167 / 183 |
kidney | 100% | 1540.99 | 89 / 89 | 87% | 14.66 | 787 / 901 |
eye | 0% | 0 | 0 / 0 | 100% | 47.89 | 80 / 80 |
muscle | 100% | 3563.48 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.36 | 1 / 1 |
blood vessel | 100% | 1638.80 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 1598.22 | 1201 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1179.36 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 98% | 2774.85 | 848 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 10.55 | 24 / 29 |
tonsil | 0% | 0 | 0 / 0 | 80% | 13.43 | 36 / 45 |
peripheral blood | 29% | 172.97 | 265 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0019538 | Biological process | protein metabolic process |
GO_0042984 | Biological process | regulation of amyloid precursor protein biosynthetic process |
GO_0009306 | Biological process | protein secretion |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0000137 | Cellular component | Golgi cis cisterna |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NECAB3 |
Protein name | N-terminal EF-hand calcium-binding protein 3 (Amyloid-beta A4 protein-binding family A member 2-binding protein) (Nek2-interacting protein 1) (Neuronal calcium-binding protein 3) (X11L-binding protein 51) N-terminal EF-hand calcium binding protein 3 |
Synonyms | SYTIP2 NIP1 XB51 APBA2BP |
Description | FUNCTION: Inhibits the interaction of APBA2 with amyloid-beta precursor protein (APP), and hence allows formation of amyloid-beta. May enhance the activity of HIF1A and thus promote glycolysis under normoxic conditions; the function requires its ABM domain and may implicate the stabilization of the interaction between HIF1AN and APBA3. . |
Accessions | U3KQC6 U3KQJ7 ENST00000607805.5 ENST00000246190.11 [Q96P71-1] ENST00000606690.5 ENST00000493590.1 ENST00000473892.1 X6RCW6 ENST00000488489.5 U3KQF5 ENST00000375238.8 [Q96P71-2] U3KQR6 U3KPZ3 U3KQ06 Q96P71 ENST00000485399.5 ENST00000439478.5 U3KQM7 ENST00000480994.5 |